

Well, all I ask is, I understand that Mr. McGraw of Pennwalt is going to testify. I do not suppose that there is any objection if I remained to hear it?

Senator NELSON. You are free to remain and can comment on the testimony of Pennwalt's testimony, and if they have any rebuttal to your comment, we are willing to accept that.

We will give everybody a chance for a full presentation, and full response in the record.

Somebody better take those amphetamines away from in front of us.

Mr. ROSTHAL. Simple possession, Mr. Chairman. It is only a misdemeanor. [Laughter.]

Mr. GORDON. Mr. Rosthal, will you remain in the room?

Mr. ROSTHAL. Yes, sir.

Senator NELSON. One more question.

For clarification—you do have a substantial amount of testimony or evidence as to diversion and abuse of amphetamines and the congeners; is that correct?

Mr. RODY. That is correct, Mr. Chairman.

Senator NELSON. And that will be presented at some early stage to the FDA?

Mr. RODY. That is correct.

Senator NELSON. And you say sometime in December?

Mr. RODY. Hopefully, I cannot give you an exact date, hopefully in December. We certainly would like to review, of course, some of the testimony that has occurred here.

Senator NELSON. Yes; and how would you describe the evidence you have, substantial, not substantial, overwhelming?

Do you have a description of the evidence of the abuse, of the use of amphetamines, and the congeners that are on the marketplace?

Mr. RODY. Sir, I think it would have to be described as very substantial.

Senator NELSON. Does that apply to those amphetamines and congeners which are being "legally prescribed" in this country through legal channels?

Mr. RODY. That is correct.

Senator NELSON. As well as diversion or illicit introduction into this country, is that evidence substantial too?

Mr. RODY. Yes, sir. Not to the same degree as it is on the amphetamines.

Senator NELSON. And do you have evidence showing widespread use and abuse?

Mr. RODY. Yes; we have data from our DAWN system which would reflect the number of episodes reported over the last 3 years in various categories of drugs.

Senator NELSON. And you consider that to be substantial?

Mr. RODY. It is reflective as being substantial, yes, sir.

Senator NELSON. Thank you very much.

Mr. RODY. Thank you.

Senator NELSON. Our next witness is Mr. Isaac McGraw, president of the pharmaceutical division of the Pennwalt Corp.

Mr. McGraw, could you please identify your associate for the record?